Shadi Kourosh, MD, MPH portrait

Dermatology

Shadi Kourosh, MD, MPH

Associate Professor of Dermatology, Harvard Medical School American Academy of Dermatology Board Member

Dr. Kourosh is Associate Professor at Harvard Medical School and the Harvard Chan School of Public Health, elected to the Board of Directors of the American Academy of Dermatology (AAD), the national leadership of the field, and served in AAD’s delegation to Congress and task force interfacing with the FDA on healthcare economics and affordable access for people with skin disease.  As an internationally recognized medical innovator particularly in novel frameworks and technologies to solve public health problems, she was named one of Medscape’s 25 Stars Leading the Future of Medicine.

As founding director of Massachusetts General Hospital’s (MGH) Dermatology Division of Community Health and the MGH Vitiligo and Pigmentary Disorder Clinic, she built and led the division providing care for underserved communities and a medical home for skin conditions such as vitiligo for which phototherapy has been a pillar of treatment. She is founding director of Harvard’s pro-bono laser clinic and tattoo removal program aiding those escaping gangs and human trafficking become safe and reintegrate into society, winning national awards for its impact.

Dr. Kourosh served as a Medical Correspondent for ABC News among many news programs, Editor in Chief of Dialogues in Dermatology, the AAD’s official podcast, Editor of the Medical Humanities section of the Journal of the American Academy of Dermatology, and contributing writer for US News & World Report. She authored the Facing Skin Conditions series of books to help people live successfully with skin conditions, featured by the National Psoriasis Foundation.

Her research at the intersection of dermatology and public health — her pioneering work on Zoom dysmorphia, skin impacts of GLP1 medications and the Covid19 vaccine, climate and pollution impacts on skin diseases and aging, and skin signs of human trafficking — has reached international impact, featured on the Today Show and at the Aspen Institute.

She has advised many companies, from multinational corporations to early-stage companies spun out of Harvard and MIT to investment funds. She was Director of the Center for Lasers and Aesthetics at Brown before joining a prestigious clinic on Park Avenue and as Director of Aesthetics for Nantucket Cottage Hospital. She publishes research and lectures globally at the intersection of aesthetics, longevity and regenerative medicine.

Dr. Kourosh has won many awards - MGH’s Clinician-Teacher Award, Harvard Medical School’s Dean’s Service Award, Top Doctors, AAD and ASLMS Presidential Citations and the International League of Dermatology Society’s Global Humanitarian Award.

HSA/FSA Eligible

Be the first to get updates from Solius Labs

Connect

Ask AI about Solius

Intertek logo
Intertek logo

Solius is an FDA-cleared over-the-counter (OTC) UVB light panel intended to stimulate production of vitamin D in people 22 years and older. The FDA regulates UVB devices intended for human use and requires them to undergo regulatory review. FDA clearance means the device's safety, performance, and labeling were reviewed by the FDA before it could be sold. UVB devices sold for human use without FDA clearance have not been reviewed for safety and may not be legally marketed. Learn why FDA clearance matters for UVB light therapy.

Solius is clinically proven to stimulate the production of vitamin D. References to the benefits of sunlight, UVB light, and vitamin D are based upon published, peer-reviewed research. The Solius device is not intended to diagnose, treat, cure, or prevent disease, except for the indications for use described in the user manual for your applicable region. Solius does not provide specific medical advice to users. Users should seek advice from a qualified physician or healthcare provider. This website does not establish a doctor-patient relationship. For detailed product information please consult the User Manual prior to use. 

Solius® is a registered trademark of Solius Labs, Inc.
100 Ravine Lane NE, Suite 310, Bainbridge Island, WA 98110

© 2026 Solius Labs, Inc.

HSA/FSA Eligible

Be the first to get updates from Solius Labs

Connect

Ask AI about Solius

Intertek logo
Intertek logo

Solius is an FDA-cleared over-the-counter (OTC) UVB light panel intended to stimulate production of vitamin D in people 22 years and older. The FDA regulates UVB devices intended for human use and requires them to undergo regulatory review. FDA clearance means the device's safety, performance, and labeling were reviewed by the FDA before it could be sold. UVB devices sold for human use without FDA clearance have not been reviewed for safety and may not be legally marketed. Learn why FDA clearance matters for UVB light therapy.

Solius is clinically proven to stimulate the production of vitamin D. References to the benefits of sunlight, UVB light, and vitamin D are based upon published, peer-reviewed research. The Solius device is not intended to diagnose, treat, cure, or prevent disease, except for the indications for use described in the user manual for your applicable region. Solius does not provide specific medical advice to users. Users should seek advice from a qualified physician or healthcare provider. This website does not establish a doctor-patient relationship. For detailed product information please consult the User Manual prior to use. 

Solius® is a registered trademark of Solius Labs, Inc.
100 Ravine Lane NE, Suite 310, Bainbridge Island, WA 98110

© 2026 Solius Labs, Inc.

HSA/FSA Eligible

Be the first to get updates from Solius Labs

Connect

Ask AI about Solius

Intertek logo
Intertek logo

Solius is an FDA-cleared over-the-counter (OTC) UVB light panel intended to stimulate production of vitamin D in people 22 years and older. The FDA regulates UVB devices intended for human use and requires them to undergo regulatory review. FDA clearance means the device's safety, performance, and labeling were reviewed by the FDA before it could be sold. UVB devices sold for human use without FDA clearance have not been reviewed for safety and may not be legally marketed. Learn why FDA clearance matters for UVB light therapy.

Solius is clinically proven to stimulate the production of vitamin D. References to the benefits of sunlight, UVB light, and vitamin D are based upon published, peer-reviewed research. The Solius device is not intended to diagnose, treat, cure, or prevent disease, except for the indications for use described in the user manual for your applicable region. Solius does not provide specific medical advice to users. Users should seek advice from a qualified physician or healthcare provider. This website does not establish a doctor-patient relationship. For detailed product information please consult the User Manual prior to use. 

Solius® is a registered trademark of Solius Labs, Inc.
100 Ravine Lane NE, Suite 310, Bainbridge Island, WA 98110

© 2026 Solius Labs, Inc.